Cargando…

1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections

BACKGROUND: Eravacycline (ERV) is a next-generation tetracycline approved for complicated intra-abdominal infections (cIAI) with in-vitro activity to multidrug-resistant organisms such as carbapenem resistant Enterobacteriaceae, extended spectrum beta-lactamase, and carbapenem-resistant Acinetobacte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carr, Amy, El Ghali, Amer, Kaur, Parminder, Minor, Sarah B, Casapao, Anthony M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776886/ http://dx.doi.org/10.1093/ofid/ofaa439.1454

Ejemplares similares

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

1243. Eravacycline in Bacteremia: A Case Series
por: Andrade, Justin A, et al.
Publicado: (2021)

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2022)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections
por: Reig, Núria, et al.
Publicado: (2020)

Draconian policy measures are unlikely to prevent disordered gaming
por: Colder Carras, Michelle, et al.
Publicado: (2021)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Reserve your judgment on “Draconian” Chinese video gaming restrictions on children •: Commentary on: Draconian policy measures are unlikely to prevent disordered gaming (Colder Carras et al., 2021)
por: Xiao, Leon Y.
Publicado: (2022)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline
por: Chua, Mary Francine P, et al.
Publicado: (2020)

An Insight into Weighing the Impact of Draconian Measures in the Battle Against COVID-19 [Letter]
por: Zehra, Syeda Sakina, et al.
Publicado: (2020)

1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
por: Rausch, Ethan, et al.
Publicado: (2022)

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
por: Van Hise, Nicholas, et al.
Publicado: (2020)

1270. Molecular Characterization of Carbapenemase Producing Enterobacterales, Acinetobacter spp. and Pseudomonas spp. in Nosocomial and Community-acquired Clinical Isolates in Bogota, Colombia
por: Reyes, Luis F, et al.
Publicado: (2021)

Case fatality rates of COVID-19 across the globe: are the current draconian measures justified?
por: Sreedharan, Jayadevan, et al.
Publicado: (2021)

1270. Population-Based Estimates of PrEP Access in Oregon, 2012–2016
por: Menza, Timothy William, et al.
Publicado: (2019)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

1607. Dual Therapy with Aztreonam & Ceftazidime/Avibactam Against Multi-Drug Resistant Stenotrophomonas maltophilia on Tricuspid Valve Endocarditis
por: Alexander, Jose, et al.
Publicado: (2020)

1601. Combination Therapy versus Monotherapy for Carbapenem-resistant Organisms: Is More Really Better?
por: Najia, Laila, et al.
Publicado: (2020)

P1270: IMMUNE REGULATORY CELLS IN B-CELL LYMPHOMAS: SIGNIFICANT HETEROGENEITY ACROSS HISTOLOGIC TYPES.
por: STAVROULAKI, M., et al.
Publicado: (2022)

514. Anti-SARS-CoV-2 Monoclonal Antibodies for Early COVID-19: A Real World Experience
por: Belden, Katherine, et al.
Publicado: (2021)

115. Influence of Antimicrobial Stewardship and Molecular Rapid Diagnostic Test on Antimicrobial Prescribing for Extended-spectrum Beta-lactamase and Carbapenemase-producing Bacteria in Bloodstream Infections
por: Coyne, Ashlan Kunz, et al.
Publicado: (2020)

P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Zeidan, Amer M., et al.
Publicado: (2023)

666. Outcomes Using Cefiderocol for the Treatment of Acinetobacter baumannii Infections from the PROVE (Real-World Evidence) Study
por: Marcella, Stephen, et al.
Publicado: (2022)

1383. Characterizing Real-world Patterns of Early Childhood Vaccination
por: Butler, Anne M, et al.
Publicado: (2020)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

Tu1270: SEROLOGICAL RESPONSE TO SARS-COV-2 VACCINES IN LIVER TRANSPLANT PATIENTS
por: Toapanta-Yanchapaxi, Liz, et al.
Publicado: (2022)

1114. Effectiveness and Safety of Beta-lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2021)

103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence
por: Tao, Li, et al.
Publicado: (2020)

898. Effectiveness and Tolerability of DTG + 3TC in Clinical Practice: Evidence in PLHIV from Real-world Data
por: Evitt, Lee A, et al.
Publicado: (2021)

644. Comparative Evaluation of ETEST® ERV bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination
por: Sauvonnet, Veronique, et al.
Publicado: (2019)

728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals
por: Iregui, Alejandro, et al.
Publicado: (2019)

710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Jones, Chelsea E, et al.
Publicado: (2019)

1270. Are HIV-Related Diagnostics Excessively Ordered? A Pilot Intervention Study to Improve Test Use in the Inpatient Setting
por: Asl, Daryush Tabatabai, et al.
Publicado: (2018)

2132. Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2019)

253 Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

Su1270: CHRONIC PANCREATITIS AND COVID-19: INCIDENCE AND OUTCOMES. A MULTICENTER RESEARCH NETWORK ANALYSIS
por: Hadi, Yousaf, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kh4vmcrd6av23apheg8u3shipb